Tiopronin (Tiopronin) Patent Expiration, LOE Window & CMS Spending

Tiopronin (Tiopronin) by Teva Pharmaceuticals: Multi-Source Generic Molecule, 4 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $8,463 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$906K
2024 Medicaid Spend$776K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($8,463 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.